Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB261 in Refractory Seropositive SLE
NCT06945068Phase 1Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GB261 in systemic lupus erythematosus (SLE). Primary endpoint: Safety and tolerability. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
GB261
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06945068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945068.